Recursion

Recursion was founded more than a decade ago on the idea that we could take images of cells and use these images to train artificial intelligence to understand the vast unknown biological space – the cellular disruptions driving disease – to use AI-drug discovery to reduce the massive 90% failure rate of traditional drug discovery. The Recursion OS drug discovery and development platform has yielded an advanced pipeline of potential first-in-class and best-in-class treatments for conditions with high unmet need including aggressive cancers and rare diseases. Today, we’ve demonstrated significant improvements in speed, efficiency, and reduced costs from hit identification to IND-enabling studies compared to traditional pharmaceutical company averages. Our strategic partnerships allow us to accelerate the discovery of new medicines and expand our potential impact on patients via AI-drug discovery.